Está en : Inicio / centros_tecnologicos / 717 / alzheimers-disease-and-memory-disorders-center

Alzheimer's Disease and Memory Disorders Center

  •  Department of Neurology Baylor College of Medicine The Medical Building 7200-B Cambridge Street, Suite E5.101 Houston, Texas 77030 Estados Unidos
  •  713-798-4734
  •  713-798-7434

The Alzheimer’s Disease and Memory Disorders Center at Baylor College of Medicine was established in 1989 and is headed by Rachelle S. Doody, M.D., Ph.D., the Effie Marie Cain Chair in Alzheimer’s Disease Research. The Center is one of only a few in the country dedicated to both patient care and research. Our focus is on the translation of discoveries made in the laboratory into improved methods of disease prevention, diagnosis, and treatment. We participate in the design or supervision of many Alzheimer’s disease or memory disorders trials taking place in the world, and we are recognized nationally and internationally for our contributions to the diagnosis and treatment of Alzheimer’s disease. The ADMDC was involved in the development of all five of the commercially available, FDA approved drugs for Alzheimer’s disease, and was the lead site for the development of the most widely prescribed Alzheimer’s disease drug worldwide. In addition to developing treatments for Alzheimer’s disease, one focus of the Center is on research trials testing interventions to prevent Alzheimer’s disease in normal subjects, as well as in individuals who are at greater risk for developing the disease. The Center is also part of a national effort to use neuroimaging techniques to develop diagnostic tests to identify or predict Alzheimer’s disease, even in persons who do not yet show symptoms of disease. Because we adopt a longitudinal approach to patient care, we are able to gather and analyze information about our patients for many years. We are using this information to create predictive models of disease progression, so that we can someday advise patients and their families in advance of what to expect over the course of their illness. We will also use this information to design clinical trials for new agents designed to slow the progression of Alzheimer’s disease.



  • Investigación
  • Medicina